Kiadis' COVID-19 announcement sends shares upwards

17 August 2020
kiadis-big

Netherlands-based Kiadis Pharma (Euronext: KDS) has announced a new research program, K-NK-ID101, that will focus on the development of K-NK cells as a treatment for COVID-19.

This new program marks the start of broader application of Kiadis’ K-NK technology platform as a potential treatment, not only for cancer, but also for infectious diseases.

In support of the K-NK-ID101 program, Kiadis has started collaborating with five Dutch institutions to study different anti-viral mechanisms of Kiadis’ K-NK cell therapy platform against SARS-CoV-2, the virus that caused the COVID-19 pandemic.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology